Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models

Objectives: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but nevertheless 30% of patients experience MTX inefficacy. Our aim was to develop a clinical pharmacogenetic model to predict which RA patients will not respond to MTX monotherapy. We also assessed whether thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenko, Barbara, Tomšič, Matija, Jekić, Biljana, Milić, Vera, Dolžan, Vita, Praprotnik, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788961/
https://www.ncbi.nlm.nih.gov/pubmed/29422864
http://dx.doi.org/10.3389/fphar.2018.00020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788961/
https://www.ncbi.nlm.nih.gov/pubmed/29422864
http://dx.doi.org/10.3389/fphar.2018.00020

Ejemplares similares